SCL Science Inc.
Financials
Valuation Metrics
SCL Science Inc.'s Market Cap is ₩791B. At end of 2025 it was ₩782B. Ranked #1432 of 2,421 in KR market (top 59%), #819 of 1,640 on KOSDAQ (top 50%), #52 of 96 in Health Care Equipment & Services (top 54%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 79.09B KRW | KR#1,432/2,421 Sec#52/96 |
| Revenue | 30.50B KRW | KR#2,026/2,421 Sec#66/96 |
| Net Income | -3.83B KRW | KR—/2,421 Sec—/96 |
| Total Assets | 78.90B KRW | KR#1,942/2,421 Sec#62/96 |
| Net Assets | 22.90B KRW | KR#2,257/2,421 Sec#83/96 |
| Employees | 63 | KR#1,940/2,421 Sec#81/96 |
| Value | ||
| P/B | 3.45x | KR#2,147/2,421 Sec#79/96 |
| P/S | 2.59x | KR#1,929/2,421 Sec#59/96 |
| FCF Yield | -3.85% | KR—/2,421 Sec—/96 |
| Profitability | ||
| ROE | -16.74% | KR#2,056/2,421 Sec#74/96 |
| ROA | -4.86% | KR#1,927/2,421 Sec#64/96 |
| Op. Margin | -3.02% | KR#1,781/2,421 Sec#54/96 |
| Revenue Growth | 225.88% | KR#34/2,421 Sec#4/96 |
| Financial Health | ||
| Debt Ratio | 244.58% | KR#2,205/2,421 Sec#89/96 |
| Total Debt | 25.83B KRW | KR#1,292/2,421 Sec#35/96 |
| FCF | -3.05B KRW | KR#1,395/2,421 Sec#46/96 |
| Cash | 3.69B KRW | KR#2,112/2,421 Sec#84/96 |
| Current Ratio | 0.57x | KR#2,101/2,421 Sec#89/96 |
| Performance | ||
| 1Y Return | -11.76% | KR#1,010/2,421 Sec#19/96 |
| 1M Return | 14.25% | KR#354/2,421 Sec#11/96 |
| From 52W High | -28.46% | KR#484/2,421 Sec#12/96 |
| 1Y MDD | -51.52% | KR#1,048/2,421 Sec#37/96 |
| Trading | ||
| Volume | 123,244 shares | KR#688/2,421 Sec#22/96 |
| Trading Value | 281.6M KRW | KR#1,142/2,421 Sec#41/96 |
| Foreign Own. | 0.50% | KR#2,208/2,421 Sec#85/96 |
| Per Share | ||
| EPS | -113 KRW | KR—/2,421 Sec—/96 |
| BPS | 673 KRW | KR#2,365/2,421 Sec#92/96 |
Company Info
SCL Science, established in 2010 and listed on KOSDAQ in 2019, is a bio venture company. It primarily develops and produces medical hemostatic agents using biomimetic technology inspired by mussel adhesion, alongside operating bio-logistics and data platform-based digital healthcare businesses. The company is developing a range of hemostatic products applicable to patients with blood coagulation disorders and expanding its product portfolio with polymer modification technology, growing into a healthcare company. SCL Science is headquartered in Yeongdeungpo-gu, Seoul.